NCT07598773
BETA: Study in Prediabetes Type 2 Diabetes
Enrolling by Invitation
Not specifiedAges 18+Observational4YouandMeInvestigator-initiated
~130 participants
Updated 2026-05-20 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility: Retention
Measured over 6-8 months
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
18+ years old
Have an established diagnosis of Prediabetes or Type 2 diabetes
Have a glycated hemoglobin (HbA1c) below 8% (64 mmol/mol) and a body mass index (BMI) between 18-40 kg/m2 that will be determined from your height and weight
Are willing to use an Abbott FreeStyle Libre 3/3+ Continuous Glucose Monitor (CGM) supplied by the study and provide the study investigators access to the CGM data
Are willing to use the study wearable devices (e.g., Oura Ring)
Are able to read, write, and speak in English
If you use long-acting insulin, you must be on a prescribed regimen where you administer it at bedtime only and no other time of day (bolus short-acting may be used at any time as needed)
All medication regimens must have a minimum of 30 days supply, and no new medications started within 30 days of enrollment
Weight must be stable (± 10 pounds) for 2 months prior to enrollment
Must have a personally owned iPhone 6s or newer (iOS 16.4+) or Android smartphone (version 12 or newer) and use this phone to download and use the study app and use the provided study devices
Must have a personally owned computer or tablet or have access to these devices at home
Must reside in the North San Francisco Bay area and be willing to travel to Novato, CA to attend two morning clinic assessments at the Buck Institute
Exclusion
Using any Abbott CGM (prescribed or OTC)
BMI \<18 kg/m2 or \>40 kg/m2
Dairy or soy allergy
Currently pregnant or breastfeeding
Diagnosed with Type 1 diabetes or MODY (Maturity-Onset Diabetes of the Young)
Using an insulin pump
Using any of the following medications: Glucocorticoids, Non-Selective Beta Blockers (e.g., propranolol), Thiazide Diuretics
Currently using tobacco products (cigarettes, vapes, chew, dip, etc.)
Hospitalized overnight for any reason in the last 3 months
History of pancreatic disease (other than diabetes) or pancreatic transplantation
Have any active malignancy within the last 12 months
History of bariatric / other gastrointestinal surgery anticipated to affect glucose metabolism / cause gastroparesis
History of systemic disease (hepatic, cardiovascular, other) likely to interfere with glucose metabolism or study participation
What this trial measures
- Feasibility: Retention6-8 months
Proportion of participants retained according to study protocol
- Feasibility: Adherence6-8 months
Mean adherence to completing in-app daily study measures